GELS
Gelteq Limited Ordinary Shares
Drug Manufacturers - Specialty & Generic
Market Cap$5M
5Y Perf.-81.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GELS vs ATXI
Revenue, margins, valuation, and 5-year total return — side by side.
ATXI
Avenue Therapeutics, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-77.1%
GELS vs ATXI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GELS | ATXI |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $5M | $2M |
| Revenue (TTM) | $148K | $1M |
| Net Income (TTM) | $-4M | $-4M |
| Gross Margin | 100.0% | 100.0% |
| Operating Margin | -87.7% | -279.8% |
| Total Debt | $4M | $0.00 |
| Cash & Equiv. | $25K | $3M |
GELS vs ATXI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GELS
ATXI
| Stock | Oct 24 | May 26 | Return |
|---|---|---|---|
| Gelteq Limited Ordi… (GELS) | 100 | 18.2 | -81.8% |
| Avenue Therapeutics… (ATXI) | 100 | 22.9 | -77.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GELS vs ATXI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATXI leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Gelteq Limited Ordinary Shares is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
GELS
Gelteq Limited Ordinary Shares
The Growth Play
GELS is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -100.0%, EPS growth 100.0%
- -84.1% 10Y total return vs ATXI's -100.0%
- -19.5% ROA vs ATXI's -105.8%
Best for: growth exposure and long-term compounding
ATXI
Avenue Therapeutics, Inc.
The Defensive Pick
ATXI carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta -0.11, current ratio 3.27x
- Beta -0.11, current ratio 3.27x
- -30.5% revenue growth vs GELS's -100.0%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATXI | -30.5% revenue growth vs GELS's -100.0% |
| Quality / Margins | ATXI | -266.7% margin vs GELS's -27.4% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXI | +150.1% vs GELS's -66.5% |
| Efficiency (ROA) | GELS | -19.5% ROA vs ATXI's -105.8% |
GELS vs ATXI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGELSLAGGINGATXI
ATXIAvenue Therapeutics, …
2leads
GELSGelteq Limited Ordina…
2leads
6 Total Categories
CATEGORYLEADERvs ATXIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATXI3/3
Valuation MetricsMultiples, price ratios, and targets
—
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GELS3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
GELS4/6
Risk & VolatilityBeta, volatility, and downside exposure
ATXI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATXI leads this category, winning 3 of 3 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATXI is the larger business by revenue, generating $1M annually — 9.5x GELS's $147,535. ATXI is the more profitable business, keeping -2.7% of every revenue dollar as net income compared to GELS's -27.4%.
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $147,535 | $1M |
| EBITDAEarnings before interest/tax | -$12M | -$4M |
| Net IncomeAfter-tax profit | -$4M | -$4M |
| Free Cash FlowCash after capex | -$2M | -$2M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -87.7% | -2.8% |
| Net MarginNet income ÷ Revenue | -27.4% | -2.7% |
| FCF MarginFCF ÷ Revenue | -12.4% | -124.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +89.1% |
ATXI leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| Market CapShares × price | $5M | $2M |
| Enterprise ValueMkt cap + debt − cash | $8M | -$842,479 |
| Trailing P/EPrice ÷ TTM EPS | — | -0.61x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 3.84x |
| Price / FCFMarket cap ÷ FCF | — | — |
Insufficient data to determine a leader in this category.
Profitability & Efficiency
GELS leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
GELS delivers a -26.8% return on equity — every $100 of shareholder capital generates $-27 in annual profit, vs $-161 for ATXI.
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -26.8% | -160.6% |
| ROA (TTM)Return on assets | -19.5% | -105.8% |
| ROICReturn on invested capital | -11.1% | — |
| ROCEReturn on capital employed | -15.5% | -9.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.25x | — |
| Net DebtTotal debt minus cash | $4M | -$3M |
| Cash & Equiv.Liquid assets | $24,522 | $3M |
| Total DebtShort + long-term debt | $4M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -6.89x | — |
GELS leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
GELS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GELS five years ago would be worth $1,585 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +150.1% total return vs GELS's -66.5%. The 3-year compound annual growth rate (CAGR) favors GELS at -45.9% vs ATXI's -80.7% — a key indicator of consistent wealth creation.
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -44.4% | -19.8% |
| 1-Year ReturnPast 12 months | -66.5% | +150.1% |
| 3-Year ReturnCumulative with dividends | -84.1% | -99.3% |
| 5-Year ReturnCumulative with dividends | -84.1% | -100.0% |
| 10-Year ReturnCumulative with dividends | -84.1% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -45.9% | -80.7% |
GELS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ATXI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATXI is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than GELS's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXI currently trades 56.7% from its 52-week high vs GELS's 13.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | -0.11x |
| 52-Week HighHighest price in past year | $3.51 | $0.97 |
| 52-Week LowLowest price in past year | $0.44 | $0.15 |
| % of 52W HighCurrent price vs 52-week peak | +13.3% | +56.7% |
| RSI (14)Momentum oscillator 0–100 | 24.0 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 18K | 3K |
ATXI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | GELSGelteq Limited Or… | ATXIAvenue Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATXI leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). GELS leads in 2 (Profitability & Efficiency, Total Returns).
Best OverallGelteq Limited Ordinary Sha… (GELS)Leads 2 of 6 categories
Loading custom metrics...
GELS vs ATXI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — GELS or ATXI?
Over the past 5 years, Gelteq Limited Ordinary Shares (GELS) delivered a total return of -84.
1%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: GELS returned -84. 1% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — GELS or ATXI?
By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.
(ATXI) is the lower-risk stock at -0. 11β versus Gelteq Limited Ordinary Shares's 1. 16β — meaning GELS is approximately -1159% more volatile than ATXI relative to the S&P 500.
03Which is growing faster — GELS or ATXI?
On earnings-per-share growth, the picture is similar: Gelteq Limited Ordinary Shares grew EPS 100.
0% year-over-year, compared to 98. 8% for Avenue Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — GELS or ATXI?
Avenue Therapeutics, Inc.
(ATXI) is the more profitable company, earning -266. 7% net margin versus -27. 4% for Gelteq Limited Ordinary Shares — meaning it keeps -266. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATXI leads at -279. 8% versus -87. 7% for GELS. At the gross margin level — before operating expenses — GELS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — GELS or ATXI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is GELS or ATXI better for a retirement portfolio?
For long-horizon retirement investors, Avenue Therapeutics, Inc.
(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ATXI: -100. 0%, GELS: -84. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between GELS and ATXI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.